Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., Dec. 9, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to $175 million of...
-
CAMBRIDGE, Mass., Dec. 9, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the...
-
AG-348 Achieved Proof-of-Mechanism Through Substantial Effects on Two Key Biomarkers of Pyruvate Kinase Activity and Pathway Activation Data Presented at ASH Support Initiation of a Phase 2 Trial...
-
CAMBRIDGE, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that...
-
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers Company Expects Global Registration Program to Begin...
-
-Significant Clinical Responses and Reduction of 2HG Biomarker Provide Early Validation of Mutant IDH1 as a Therapeutic Target in AML - -Data Support Initiation of Multiple Expansion Cohorts in...
-
CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today reported...
-
New Data from Ongoing Phase 1 AG-221 Trial Accepted for Oral Presentation Poster Presentation to Reveal First Clinical Data for AG-348, a Potential Treatment for Pyruvate Kinase Deficiency...
-
CAMBRIDGE, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced...
-
CAMBRIDGE, Mass., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the...